G-744

  Cat. No.:  DC11776  
Chemical Structure
1346669-54-2
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
G-744 is a highly potent, selective inhibitor of BTK with biochemical Ki of 1.28 nM.
Cas No.: 1346669-54-2
Chemical Name: 2-(2-(hydroxymethyl)-3-(1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydropyridin-3-yl)phenyl)-6,6-dimethyl-3,4,6,7-tetrahydro-2H-cyclopenta[4,5]thieno[2,3-c]pyridin-1(5H)-one
Synonyms: G 744;G744
SMILES: C(=O)1N(C2=CC=CC(C3C=C(NC4C=CN=CN=4)C(=O)N(C)C=3)=C2CO)CCC2C3CC(C)(C)CC=3SC1=2
Formula: C29H29N5O3S
M.Wt: 527.643
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: G-744 is a highly potent, selective inhibitor of BTK with biochemical Ki of 1.28 nM; demonstrates >1,000-fold selectivity against a panel 285 kinase (exception with EphA7 and Fgr, 400-800 fold); prevents BCR-mediated CD86 induction (EC50=64 nM), also inhibits BCR-stimulated B-cell proliferation in human B-cells (EC50=22 nM), abrogates production of TNFα in human monocytes (EC50=33 nM); demonstrates efficacy in the developing CIA model in rats.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC47719 BTK inhibitor 19 BTK inhibitor 19 is a highly selective, covalent BTK inhibitor (IC50 = 2.7 nM).
DC46928 TL-895 TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer research.
DC46051 Zanubrutinib D5 Zanubrutinib D5 (BGB-3111 D5) is deuterium labeled Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (Btk) inhibitor.
DC45785 Elsubrutinib Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor。The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease.
DC44005 BTK inhibitor 17 BTK inhibitor 17 is a potent and orally active irreversible BTK inhibitor with an IC50 of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research.
DC42422 IBT6A hydrochloride IBT6A hydrochloride is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk with an IC50 of 0.5 nM.
DC42421 IBT6A IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk with an IC50 of 0.5 nM.
DC41149 Ibrutinib deacryloylpiperidine Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
DC41102 Acalabrutinib D4 Acalabrutinib D4 (ACP-196 D4) is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor.
DC11776 G-744 G-744 is a highly potent, selective inhibitor of BTK with biochemical Ki of 1.28 nM.
X